Table 7.
Treatment-related adverse events in patients with hepatocellular carcinoma, n (%)
|
Variable
|
Group
|
P value
|
|
|
HBV-DNA > 2000, n = 54
|
HBV-DNA ≤ 2000, n = 66
|
||
| Rash | 4 (7) | 6 (9) | > 0.999 |
| Nausea | 7 (13) | 13 (20) | 0.325 |
| Diarrhea | 5 (9) | 5 (8) | 0.752 |
| Fatigue | 4 (7) | 6 (9) | > 0.999 |
| Myocarditis | 6 (11) | 6 (9) | 0.714 |
| Hyperbilirubinemia | 5 (9) | 8 (12) | 0.616 |
| Hypertension | 5 (9) | 7 (11) | 0.807 |
| Leukopenia | 6 (11) | 8 (12) | 0.864 |
| Thrombocytopenia | 7 (13) | 10 (15) | 0.732 |
| RCCEP | 23 (43) | 31 (47) | 0.632 |
| Neutropenia | 4 (7) | 7 (11) | 0.752 |
| Proteinuria | 14 (26) | 18 (27) | 0.868 |
| Hypothyroidism | 5 (9) | 5 (8) | 0.752 |
| Elevated ALT | 4 (7) | 7 (11) | 0.752 |
| Elevated AST | 7 (13) | 6 (9) | 0.497 |
Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; RCCEP: Reactive cutaneous capillary endothelial proliferation; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.